+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-Oncology Market - Global Forecast 2026-2032- Product Image
Immuno-Oncology Market - Global Forecast 2026-2032- Product Image
New

Immuno-Oncology Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889363
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Immuno-oncology is reshaping the landscape of oncology-focused healthcare as advancements in scientific research, technology, and operational efficiency expand therapeutic possibilities and commercial prospects. Senior leaders in this dynamic sector must harmonize innovation with manufacturing and regulatory strategies to sustain a competitive advantage.

Market Snapshot: Immuno-Oncology Market Trends

Between 2025 and 2026, the Immuno-Oncology Market grew from USD 6.49 billion to USD 7.16 billion, and is forecast to maintain momentum, advancing at a CAGR of 10.30% to reach USD 12.91 billion by 2032. Market expansion is being propelled by a steady stream of scientific innovations, broader treatment pipelines, and refined commercialization strategies. These trends are positioning immuno-oncology as an increasingly vital pillar in addressing unmet needs in cancer treatment across the global healthcare spectrum. Emerging science and evolving regulatory pathways are encouraging more enterprises to stake significant investments in pipeline development, cross-border partnerships, and technology integration, accelerating the overall market transformation.

Scope & Segmentation

This report delivers a thorough analysis that bridges key scientific, operational, and commercial dimensions, guiding stakeholders through the complex field of immuno-oncology. The segmentation ensures comprehensive coverage across major dimensions:

  • Therapy Modalities: Cancer vaccines (such as dendritic cell, DNA, and peptide), cell therapy (including CAR-T, NK cell, TCR-T, with clear tracking of autologous and allogeneic CAR-T), checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokines, and oncolytic viruses are profiled, enabling targeted therapeutic analysis.
  • Indications: Includes breast, colorectal, and lung cancers—with details on subtypes like Her2-positive, triple-negative, and cell classification—alongside lymphoma and both cutaneous and uveal melanoma.
  • End Users: Encompasses academic institutes, cancer research centers, clinics, and hospitals, reflecting diversity in infrastructure, procurement, and care delivery models.
  • Lines of Therapy: Examines strategies across first to fourth line and additional treatment settings, each demanding specific clinical development and regulatory approaches.
  • Mechanisms: Covers active immunotherapy (e.g., vaccines, cytokines) and passive immunotherapy approaches (adoptive cell transfer including CAR-T and TCR-T, checkpoint inhibitors, monoclonal antibodies), illustrating the diversity of immune-based cancer interventions.
  • Platforms & Technology: Highlights advances in cell engineering, neoantigen targeting, modern sequencing, computational biology, and automation, underscoring the technology-driven evolution of the field.
  • Geographic Regions: Analyzes dynamics within the Americas, Europe, Middle East & Africa, and Asia-Pacific, acknowledging varying regulatory environments, investment climates, and clinical infrastructures in each region.

Key Takeaways for Senior Leaders

  • Continuous advancements in cell and molecular engineering are broadening therapeutic opportunities and facilitating new collaborations and investor relationships.
  • Operational challenges such as scaling manufacturing and generating real-world evidence are increasingly integral to strategy given heightened demands from regulators and payers globally.
  • Partnership models are diversifying, as cooperation between industry, academia, and contract development and manufacturing organizations accelerates both innovation adoption and portfolio expansion.
  • Localized strategies are essential since each major geographic region presents unique regulatory pathways, commercialization timelines, and patient access considerations.
  • Early integration of biomarker-driven approaches into clinical programs enhances both research efficiency and supports favorable engagement with payers and stakeholders, facilitating smoother market introduction and sustainability.
  • Clear segmentation—by therapy type, indication, and clinical pathway—enables more precise investment prioritization and sequencing, refining the pathway from development to commercialization.

Tariff Impact: Navigating 2025 Policy Shifts

Recent changes to tariffs on laboratory reagents, bioprocessing consumables, and instrumentation present new challenges for immuno-oncology firms by raising supply chain expenses and driving a re-examination of sourcing strategies. Organizations are responding by regionalizing production networks, forging local supply partnerships, and deploying process optimization initiatives. These approaches not only support cost containment and resilience amid ongoing policy shifts but also prompt sponsors to design more efficient clinical studies and develop adaptive contracting models to effectively manage future pricing uncertainty and ensure access.

Methodology & Data Sources

The report applies a mixed-method analysis, integrating direct interviews with clinical, manufacturing, payer, and sector experts, and supplementing findings through comprehensive secondary review of literature, clinical trials data, guidance, and patents. This combined methodology validates both qualitative and quantitative insights, ensuring actionable recommendations aligned with real-world experience.

Why This Report Matters

  • Provides strategic direction by mapping technology use, segmented market opportunities, and critical regulatory shifts for informed immuno-oncology planning and investment decisions.
  • Enables executive and cross-functional leaders to proactively address risks related to evolving tariffs, supply chain disruptions, and payer requirements.
  • Facilitates benchmarking of development priorities and evaluation of collaboration models in a complex, fast-evolving landscape.

Conclusion

Sustainable success in immuno-oncology now depends on blending scientific progress with operational agility and evidence-based engagement. Leaders who emphasize manufacturing robustness, biomarker integration, and adaptable partnerships will be well-positioned for enduring impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immuno-Oncology Market, by Therapy Type
8.1. Cancer Vaccines
8.2. Cell Therapy
8.2.1. CAR-T Therapy
8.2.1.1. Allogeneic
8.2.1.2. Autologous
8.2.2. NK Cell Therapy
8.2.3. TCR-T Therapy
8.3. Checkpoint Inhibitors
8.3.1. CTLA-4 Inhibitors
8.3.2. PD-1 Inhibitors
8.3.3. PD-L1 Inhibitors
8.4. Cytokines
8.5. Oncolytic Viruses
9. Immuno-Oncology Market, by Indication
9.1. Breast Cancer
9.1.1. Her2-Positive Breast Cancer
9.1.2. Triple-Negative Breast Cancer
9.2. Colorectal Cancer
9.3. Lung Cancer
9.3.1. Nsclc
9.3.2. Small Cell Lung Cancer
9.4. Lymphoma
9.5. Melanoma
9.5.1. Cutaneous Melanoma
9.5.2. Uveal Melanoma
10. Immuno-Oncology Market, by Line Of Therapy
10.1. First Line
10.2. Fourth Line Or Beyond
10.3. Second Line
10.4. Third Line
11. Immuno-Oncology Market, by End User
11.1. Academic Institutes
11.2. Cancer Research Institutes
11.3. Clinics
11.4. Hospitals
12. Immuno-Oncology Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Immuno-Oncology Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Immuno-Oncology Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Immuno-Oncology Market
16. China Immuno-Oncology Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Agenus Inc.
17.6. Allogene Therapeutics, Inc.
17.7. Amgen Inc.
17.8. AstraZeneca PLC
17.9. Autolus Limited
17.10. BeiGene, Ltd.
17.11. BioNTech SE
17.12. Bristol-Myers Squibb Company
17.13. Celgene Corporation
17.14. Eli Lilly and Company
17.15. Gilead Sciences, Inc.
17.16. GlaxoSmithKline plc
17.17. Immutep Ltd.
17.18. Johnson & Johnson
17.19. Juno Therapeutics, Inc.
17.20. Legend Biotech Corporation
17.21. Merck & Co., Inc.
17.22. Moderna, Inc.
17.23. Novartis AG
17.24. Pfizer Inc.
17.25. Regeneron Pharmaceuticals, Inc.
17.26. Roche Holding AG
17.27. Sanofi S.A.
17.28. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 155. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 156. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 157. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 160. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 161. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 162. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 177. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 178. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 179. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 180. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 181. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 182. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 183. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 184. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 198. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 200. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 201. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 202. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 203. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 204. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 205. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 206. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 207. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 211. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 212. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 213. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 215. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 216. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 217. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 218. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 219. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 233. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 234. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 235. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 237. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 238. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 239. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 240. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 241. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 244. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 245. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 246. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 247. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 248. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 249. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 250. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 251. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 252. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 254. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 255. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 256. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 257. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 259. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 260. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 261. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 262. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 263. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 277. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 278. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 279. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
TABLE 280. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 281. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 282. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 283. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 284. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 285. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 286. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Immuno-Oncology market report include:
  • Agenus Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Limited
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Johnson & Johnson
  • Juno Therapeutics, Inc.
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.16 Billion
Forecasted Market Value ( USD ) by 2032 $ 12.91 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032 - Product Image

Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides - Product Image

Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides

  • Report
  • 262 Pages
  • Global
From
Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.